Tirzepatide (The Dual Agonist) Explained Unlike semaglutide, tirzepatide is a dual GIP/GLP-1 agonist
With the support of my health care team, Im working to come to terms with the childhood trauma that led to my eating disorder
Harvard Health Publishing: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
Prescription GLP-1 medications mimic the bodys own GLP-1 hormone, directly activating GLP-1 receptors to produce clinically significant effects, such as appetite suppression, improved insulin response, and weight loss
These differences may also explain differences in gastrointestinal adverse reactions, such as nausea and vomiting, which are common with GLP-1RAs but typically diminish over time [127, 128]
They recognize that clinical trials showed modest effects (average 2.6 kg over 12 weeks in responders), appreciate that individual response varies significantly, commit to proper nutrition and exercise foundations, and accept that the peptide is used for research purposes under medical supervision